Health X Platform Ltd (HEALTHX)

📊 Quarterly Results (₹ Cr)

Revenue has grown consistently over the past four quarters, rising from ₹301 crores in September 2025 to ₹447 crores in June 2026, indicating accelerating top-line momentum. Operating performance has improved sequentially, with OPM moving from -8.0% in September 2025 to -2.4% in June 2026, suggesting better cost management. Despite this, net losses persist, with NP improving from ₹-15 crores to ₹2 crores over the same period, reflecting progress but not yet profitability. The trajectory aligns with management’s stated focus on scaling B2B operations and restructuring for long-term efficiency.

🔮 Management Outlook & What's Next

Management has provided a long-term revenue target of ₹6,000 crores by FY30, with a strategic split of ₹4,000 crores from B2B and ₹2,000 crores from B2C. This indicates a clear roadmap focused on scaling enterprise services while maintaining consumer growth. No near-term profitability guidance was given, but the emphasis on margin improvement and operational restructuring suggests a deliberate pace of investment ahead of sustainable earnings. The company did not provide forward guidance on margins or timelines for turning profitable in the latest filings.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable capital structure with negligible net debt (Total Borrowings of ₹26 crores as of March 2026) and growing equity and reserves, which increased from ₹638 crores to ₹650 crores. Total assets rose to ₹1,008 crores, indicating asset base expansion in line with revenue growth. There is no evidence of aggressive deleveraging or large-scale capital returns; instead, the focus appears to be on organic growth and structural reorganization. Reserves and surplus have steadily increased, supporting a conservative capital allocation strategy.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at around 74%, indicating confidence in the company’s long-term vision. Institutional ownership (FII and DII) has been gradually increasing over the past four quarters, with FII rising from 2.04% to 2.29% and DII from 2.07% to 2.6%, suggesting growing institutional interest. The number of public shareholders has declined slightly, but overall shareholder dispersion remains broad. No significant selling by promoters or institutions has been observed, and the shareholder base is stabilizing.

⚖️ Peer Comparison — Finance

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) The company continues to operate at a net loss and negative operating cash flow, with no clear timeline for profitability despite revenue growth. 2) The successful execution of the composite scheme of arrangement and demerger into Microsec Resources Ltd is critical but subject to regulatory and shareholder approval risks. 3) The long-term revenue target of ₹6,000 crores by FY30 is ambitious and depends on sustained B2B growth, which has not yet been proven at scale. 4) High promoter concentration (74%) may limit float liquidity and increase vulnerability to large trades.

📋 Recent Filings

• 🟡 voting results2026-09-29Health X Platform Ltd announced voting results from its 37th Annual General Meeting held on 28 September 2026, where all seven agenda items were appro…
• 🟡 Board Meeting2026-09-29Health X Platform Limited announced voting results from its 37th AGM held on 28 September 2026, where all seven agenda items were passed with requisit…
• 🟡 Board Meeting2026-09-28Health X Platform held its 37th AGM on 28 September 2026 via video conference, with 104 shareholders present. The Chairman highlighted strategic progr…
• Announcement2026-09-25Health X Platform Ltd announced that its trading window will close on 1st October 2026 for all designated persons and their immediate relatives until …
• 🔴 annual report2026-09-04Health X Platform Limited disclosed that it sent a letter to shareholders without registered email addresses, providing the web-link and exact path to…
• 🔴 annual report2026-09-04Health X Platform Ltd (HEALTHX) reported a consolidated revenue of **₹1,31,926.59 Lakhs** and a net loss of **₹(144.73) Lakhs** for FY 2025-26, reflec…
• 🟡 Board Meeting2026-09-04Health X Platform Limited announced its 37th Annual General Meeting scheduled for September 28, 2026 at 3:00 PM IST via video conferencing. Shareholde…
• 🟡 sustainability report2026-09-04Health X Platform Limited (HEALTHX) filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 on September 4, 2026, disclosing…
• 🟡 Board Meeting2026-08-31Health X Platform Limited announced its 37th Annual General Meeting will be held on 28 September 2026 at 3.00 PM IST via video conference, with the An…
• Announcement2026-08-25Health X Platform Limited announced a scheduled group conference call with analysts and investors on Monday, 31st August 2026, from 2:00 PM to 3:30 PM…

🧠 Analyst's Read

Health X Platform is executing a clear restructuring plan to scale its B2B operations and achieve ₹6,000 crores in revenue by FY30, supported by improving operational efficiency and stable institutional interest. However, persistent losses, negative cash flow, and execution risks in its reorganization strategy remain key concerns. Investors should monitor the progress of the demerger, upcoming Q1 FY27 results, and any updates on profitability timelines during the upcoming AGM and future filings.

Based on filing content and financial data. Not a recommendation.